Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps

Omalizumab is a biological drug targeting circulating IgE, approved for use in allergic asthma, chronic spontaneous urticaria, and recently for chronic rhinosinusitis with nasal polyps, with good efficacy in all these settings. Some concerns about omalizumab safety have been raised as its use has be...

Full description

Bibliographic Details
Main Authors: Diego Bagnasco, MD, PhD, Rikki Frank Canevari, MD, Stefano Del Giacco, MD, Silvia Ferrucci, MD, Paolo Pigatto, MD, Paolo Castelnuovo, MD, Gian Luigi Marseglia, MD, Arzu Didem Yalcin, MD, Girolamo Pelaia, MD, Giorgio Walter Canonica, MD
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:World Allergy Organization Journal
Subjects:
Severe asthma
Omalizumab
Cancer
Anti IgE
Monoclonal antibodies
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455122000977

Internet

http://www.sciencedirect.com/science/article/pii/S1939455122000977

Similar Items